Does the media favor EWTX or ASND?

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.66 beat Ascendis Pharma A/S's score of 0.64 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EWTX or BBIO?

In the previous week, BridgeBio Pharma had 6 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 10 mentions for BridgeBio Pharma and 4 mentions for Edgewise Therapeutics. BridgeBio Pharma's average media sentiment score of 0.72 beat Edgewise Therapeutics' score of 0.66 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer EWTX or ELAN?

In the previous week, Elanco Animal Health had 4 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 8 mentions for Elanco Animal Health and 4 mentions for Edgewise Therapeutics. Elanco Animal Health's average media sentiment score of 1.37 beat Edgewise Therapeutics' score of 0.66 indicating that Elanco Animal Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elanco Animal Health 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AXSM or EWTX?

In the previous week, Axsome Therapeutics had 9 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 13 mentions for Axsome Therapeutics and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.66 beat Axsome Therapeutics' score of 0.61 indicating that Edgewise Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 3 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, EWTX or SMMT?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.66 N/A Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A

Is EWTX or SMMT more profitable?

Edgewise Therapeutics' return on equity of -32.55% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -32.55% -31.04% Summit Therapeutics N/A -291.24% -243.07%

Does the media refer more to EWTX or SMMT?

In the previous week, Summit Therapeutics had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 5 mentions for Summit Therapeutics and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.66 beat Summit Therapeutics' score of 0.42 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Edgewise Therapeutics (EWTX) Competitors

$38.81 -0.95 (-2.39%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$39.29 +0.48 (+1.24%)

As of 08:46 AM Eastern

Compare

EWTX vs. ASND, BBIO, ELAN, AXSM, and SMMT

Should you buy Edgewise Therapeutics stock or one of its competitors? MarketBeat compares Edgewise Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Edgewise Therapeutics include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Axsome Therapeutics (AXSM), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Edgewise Therapeutics (NASDAQ:EWTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Ascendis Pharma A/S has a net margin of 57.87% compared to Edgewise Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

In the previous week, Ascendis Pharma A/S had 2 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 6 mentions for Ascendis Pharma A/S and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.66 beat Ascendis Pharma A/S's score of 0.64 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

Edgewise Therapeutics has higher earnings, but lower revenue than Ascendis Pharma A/S. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Ascendis Pharma A/S	$865.78M	18.14	-$258M	$8.67	29.04

Edgewise Therapeutics currently has a consensus price target of $48.75, indicating a potential upside of 25.61%. Ascendis Pharma A/S has a consensus price target of $295.67, indicating a potential upside of 17.44%. Given Edgewise Therapeutics' higher possible upside, equities analysts clearly believe Edgewise Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05

Summary

Ascendis Pharma A/S beats Edgewise Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Edgewise Therapeutics (NASDAQ:EWTX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

99.9% of BridgeBio Pharma shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Edgewise Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
BridgeBio Pharma	$502.08M	31.50	-$724.93M	-$3.74	N/A

Edgewise Therapeutics currently has a consensus target price of $48.75, suggesting a potential upside of 25.61%. BridgeBio Pharma has a consensus target price of $95.21, suggesting a potential upside of 17.89%. Given Edgewise Therapeutics' higher possible upside, equities analysts clearly believe Edgewise Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, BridgeBio Pharma had 6 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 10 mentions for BridgeBio Pharma and 4 mentions for Edgewise Therapeutics. BridgeBio Pharma's average media sentiment score of 0.72 beat Edgewise Therapeutics' score of 0.66 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Edgewise Therapeutics has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Summary

BridgeBio Pharma beats Edgewise Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Elanco Animal Health?

Edgewise Therapeutics (NASDAQ:EWTX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Edgewise Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Elanco Animal Health has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market.

Edgewise Therapeutics currently has a consensus price target of $48.75, indicating a potential upside of 25.61%. Elanco Animal Health has a consensus price target of $28.55, indicating a potential upside of 13.39%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Edgewise Therapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Elanco Animal Health had 4 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 8 mentions for Elanco Animal Health and 4 mentions for Edgewise Therapeutics. Elanco Animal Health's average media sentiment score of 1.37 beat Edgewise Therapeutics' score of 0.66 indicating that Elanco Animal Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has higher earnings, but lower revenue than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Elanco Animal Health	$4.72B	2.67	-$232M	-$0.50	N/A

97.5% of Elanco Animal Health shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 1.1% of Elanco Animal Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Edgewise Therapeutics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Elanco Animal Health	-4.95%	7.42%	3.66%

Summary

Elanco Animal Health beats Edgewise Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Edgewise Therapeutics (NASDAQ:EWTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Edgewise Therapeutics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.86	-$183.17M	-$3.73	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A

Axsome Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Axsome Therapeutics had 9 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 13 mentions for Axsome Therapeutics and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.66 beat Axsome Therapeutics' score of 0.61 indicating that Edgewise Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	5 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Edgewise Therapeutics' return on equity of -32.55% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Edgewise Therapeutics	N/A	-32.55%	-31.04%

Axsome Therapeutics presently has a consensus price target of $261.48, indicating a potential upside of 17.97%. Edgewise Therapeutics has a consensus price target of $48.75, indicating a potential upside of 25.61%. Given Edgewise Therapeutics' higher possible upside, analysts plainly believe Edgewise Therapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Edgewise Therapeutics beats Axsome Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Edgewise Therapeutics compare to Summit Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Edgewise Therapeutics' return on equity of -32.55% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Summit Therapeutics	N/A	-291.24%	-243.07%

4.6% of Summit Therapeutics shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

In the previous week, Summit Therapeutics had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 5 mentions for Summit Therapeutics and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.66 beat Summit Therapeutics' score of 0.42 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics presently has a consensus price target of $48.75, indicating a potential upside of 25.61%. Summit Therapeutics has a consensus price target of $26.97, indicating a potential upside of 99.80%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Edgewise Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.26, suggesting that its share price is 226% less volatile than the broader market.

Summary

Edgewise Therapeutics beats Summit Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Edgewise Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EWTX vs. The Competition

Export

Metric	Edgewise Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.28B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-23.38	20.49	27.07	23.95
Price / Sales	N/A	300.33	519.31	90.33
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	7.87	7.92	10.62	6.14
Net Income	-$167.79M	$23.81M	$3.60B	$331.74M
7 Day Performance	-2.32%	-1.09%	-1.26%	-1.82%
1 Month Performance	5.25%	2.56%	1.07%	-1.45%
1 Year Performance	189.84%	42.16%	23.63%	16.32%

Edgewise Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EWTX Edgewise Therapeutics	3.1668 of 5 stars	$38.81 -2.4%	$48.75 +25.6%	+186.6%	$4.28B	N/A	N/A	60	Analyst Forecast
ASND Ascendis Pharma A/S	4.4428 of 5 stars	$265.57 +0.1%	$295.67 +11.3%	+48.2%	$16.57B	$814.57M	30.63	1,189	Analyst Downgrade
BBIO BridgeBio Pharma	3.6033 of 5 stars	$84.09 +1.2%	$94.63 +12.5%	+73.6%	$16.47B	$502.08M	N/A	400
ELAN Elanco Animal Health	3.9269 of 5 stars	$25.56 +1.7%	$28.55 +11.7%	+70.3%	$12.77B	$4.72B	N/A	9,400	News Coverage Positive News
AXSM Axsome Therapeutics	3.9684 of 5 stars	$235.26 +3.1%	$259.05 +10.1%	+98.4%	$12.11B	$638.50M	N/A	380	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EWTX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. ASND, BBIO, ELAN, AXSM, and SMMT

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Summary

How does Edgewise Therapeutics compare to Elanco Animal Health?

Summary

How does Edgewise Therapeutics compare to Axsome Therapeutics?

Summary

How does Edgewise Therapeutics compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edgewise Therapeutics (EWTX) Competitors

EWTX vs. ASND, BBIO, ELAN, AXSM, and SMMT

How does Edgewise Therapeutics compare to Ascendis Pharma A/S?

Is EWTX or ASND more profitable?

Does the media favor EWTX or ASND?

Which has more risk and volatility, EWTX or ASND?

Which has higher earnings and valuation, EWTX or ASND?

Do analysts recommend EWTX or ASND?

Summary

How does Edgewise Therapeutics compare to BridgeBio Pharma?

Do institutionals & insiders have more ownership in EWTX or BBIO?

Which has preferable earnings and valuation, EWTX or BBIO?

Do analysts recommend EWTX or BBIO?

Does the media prefer EWTX or BBIO?

Is EWTX or BBIO more profitable?

Which has more volatility & risk, EWTX or BBIO?

Summary

How does Edgewise Therapeutics compare to Elanco Animal Health?

Which has more volatility & risk, EWTX or ELAN?

Do analysts prefer EWTX or ELAN?

Does the media prefer EWTX or ELAN?

Which has higher valuation and earnings, EWTX or ELAN?

Do institutionals & insiders believe in EWTX or ELAN?

Is EWTX or ELAN more profitable?

Summary

How does Edgewise Therapeutics compare to Axsome Therapeutics?

Which has better earnings & valuation, AXSM or EWTX?

Which has more volatility & risk, AXSM or EWTX?

Do institutionals and insiders believe in AXSM or EWTX?

Does the media refer more to AXSM or EWTX?

Is AXSM or EWTX more profitable?

Do analysts recommend AXSM or EWTX?

Summary

How does Edgewise Therapeutics compare to Summit Therapeutics?

Is EWTX or SMMT more profitable?

Do insiders & institutionals hold more shares of EWTX or SMMT?

Which has stronger valuation & earnings, EWTX or SMMT?

Does the media refer more to EWTX or SMMT?

Do analysts prefer EWTX or SMMT?

Which has more volatility and risk, EWTX or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EWTX vs. The Competition

Edgewise Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools